Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
about
Changing needs of community-acquired pneumonia.Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumoniaSingle- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjectsCritical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections.Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis.In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance ProgramActivity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.Ceftaroline Resistance by Clone-Specific Polymorphism in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus
P2860
Q35127530-43FC5D98-59D2-4D1D-8E75-4B9FFA5FA1E5Q35752997-C4878915-1290-4EE9-B29E-D5BD41D1DDA9Q36667104-D20FBD0A-E149-4E6A-BB00-62CE4C0DB47AQ38006689-BE0F9C9C-B2B7-41DE-AA6E-4B3674566BC1Q40046123-717B7007-47DF-40D9-A4EE-1563394CF4B6Q40390434-42C1484E-8106-4CB8-B254-62C72098BD6FQ40976207-9444C393-441F-4DF3-BDD0-098A5CA7F2A2Q41919138-C55CB069-B5AF-4FCA-8C6C-3B14675FB48FQ41985451-1D1F5383-F9B1-432B-B8A0-95BC1C32D7BDQ47705232-D788250A-9E3A-4A11-9BC6-C42F6AD7D009Q50916931-8D969E1C-5870-4FC7-A6A0-4600380A9234Q57210839-8BA257D6-3836-41B0-9273-1EA9A990AAF5
P2860
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
@en
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
@nl
type
label
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
@en
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
@nl
prefLabel
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
@en
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
@nl
P2093
P356
P1476
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
@en
P2093
Alena Jandourek
Dirk A Thye
Donald Biek
H David Friedland
Ian A Critchley
Paul B Eckburg
P304
P356
10.1093/JAC/DKR098
P407
P478
66 Suppl 3
P577
2011-04-01T00:00:00Z